A Phase 3 interventional study of telmisartan/amlodipine 40/5 mg fixed combination and telmisartan/amlodipine 80/5 mg fixed combination in Hypertension, sponsored by Boehringer Ingelheim. Completed at 122 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-13.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 12th largest by enrollment of the 74 interventional ones that give a count, is one of 4 that started in 2008, is one of 43 in phase 3, and was the 33rd registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 48 more countries
Ages 18+
By country, each count listing its studies:
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 976 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 381 across the 74 interventional studies, 3,252 across the 48 observational. Of the 120 that completed or were terminated, 41 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 122 studies in Hypertension by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations telmisartan 40 mg / amlodipine 5 mg (T40/A5) or telmisartan 80 mg / amlodipine 5 mg (T80/A5) during long-term open-label treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trough Seated Diastolic Blood Pressure (DBP) Control
The number of patients who reach the target DBP of \<90mmHg
Time frame: End of study (34 weeks or last value on treatment)
Trough Seated Systolic Blood Pressure (SBP) Control
The number of patients who reach the target SBP of \<140mmHg
Time frame: End of study (34 weeks or last value on treatment)
Change From Baseline in Trough Seated Diastolic Blood Pressure
Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.5.
Time frame: End of study (34 weeks or last value on treatment)
Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7
The difference between the last available troughs represents the additional reduction in DBP in this study
Time frame: End of study (34 weeks or last value on treatment)
Change From Baseline in Trough Seated Systolic Blood Pressure
Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.5.
Time frame: End of study (34 weeks or last value on treatment)
Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7
The difference between the last available troughs represents the additional reduction in SBP in this study
Time frame: End of study (34 weeks or last value on treatment)
Trough Seated DBP Response
The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg
Time frame: End of study (34 weeks or last value on treatment)
Trough Seated SBP Response
The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg
Time frame: End of study (34 weeks or last value on treatment)
Trough Blood Pressure (BP) Normality Classes
The number of patients who reach predefined BP categories
Time frame: End of study (34 weeks or last value on treatment)
Time to First Additional Antihypertensive
Time from first intake of medication to first intake of an antihypertensive other than the study drug
Time frame: At any point during open-label treatment
Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control
The number of patients with DBP control (DBP\<90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment
Time frame: At any point during open-label treatment
Additional Reduction in DBP by Use of Additional Antihypertensive Therapy
Difference in trough DBP from last visit before add-on therapy and last visit during 1235.7
Time frame: At any point during open-label treatment
Additional Reduction in SBP by Use of Additional Antihypertensive Therapy
Difference in trough SBP from last visit before add-on therapy and last visit during 1235.7
Time frame: At any point during open-label treatment
Trough DBP Control Pre- and Post- Uptitration
The number of patients with DBP control (DBP\<90 mmHg). Last trough DBP measurement before uptitration to Telmisartan 80mg compared to first trough DBP taken after uptitration
Time frame: At any point during open-label treatment
| Milestone | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive |
|---|---|---|---|---|
| Started | 564 | 206 | 25 | 181 |
| Completed | 529 | 198 | 24 | 179 |
| Not completed | 35 | 8 | 1 | 2 |
| Withdrew: Adverse event | 14 | 4 | 0 | 0 |
| Withdrew: Lost to follow-up | 6 | 1 | 0 | 0 |
| Withdrew: Non compliant with the protocol | 12 | 2 | 1 | 2 |
| Withdrew: Consent withdrawn | 3 | 1 | 0 | 0 |
The number of patients who reach the target DBP of \<90mmHg
| Participants | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive |
|---|---|---|---|---|
| Yes (DBP<90 mmHg) | 504 | 160 | 19 | 84 |
| No (DBP>=90 mmHg) | 49 | 46 | 6 | 97 |
The number of patients who reach the target SBP of \<140mmHg
| Participants | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive |
|---|---|---|---|---|
| Yes (SBP<140 mmHg) | 440 | 142 | 16 | 89 |
| No (SBP>=140 mmHg) | 113 | 64 | 9 | 92 |
Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.5.
| mmHg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive |
|---|---|---|---|---|
| Change From Baseline in Trough Seated Diastolic Blood Pressure | -14.18 ± 0.31 | -12.64 ± 0.52 | -9.47 ± 1.51 | -10.17 ± 0.56 |
The difference between the last available troughs represents the additional reduction in DBP in this study
| mmHg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive |
|---|---|---|---|---|
| Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7 | -3.54 ± 0.33 | -5.52 ± 0.55 | -5.51 ± 1.59 | -5.74 ± 0.58 |
Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.5.
| mmHg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive |
|---|---|---|---|---|
| Change From Baseline in Trough Seated Systolic Blood Pressure | -17.79 ± 0.52 | -15.91 ± 0.86 | -12.6 ± 2.5 | -14.04 ± 0.92 |
The difference between the last available troughs represents the additional reduction in SBP in this study
| mmHg | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive |
|---|---|---|---|---|
| Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7 | -4.14 ± 0.5 | -5.62 ± 0.83 | -3.6 ± 2.41 | -7.17 ± 0.88 |
The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg
| Participants | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive |
|---|---|---|---|---|
| Yes (Responder) | 504 | 171 | 19 | 108 |
| No (Non-responder) | 45 | 32 | 5 | 68 |
The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg
| Participants | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive |
|---|---|---|---|---|
| Yes (Responder) | 490 | 179 | 18 | 128 |
| No (Non-responder) | 59 | 24 | 6 | 48 |
The number of patients who reach predefined BP categories
| Participants | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive |
|---|---|---|---|---|
| Optimal (SBP<120 and DBP<80 mmHg) | 67 | 4 | 1 | 6 |
| Normal (SBP<130 and DBP<85 mmHg and not optimal) | 188 | 29 | 3 | 12 |
| High-normal (SBP<140 DBP<90 mmHg and not normal) | 163 | 92 | 9 | 34 |
| Stage 1 hypertension (SBP<160 and DBP<100 mmHg | 122 | 73 | 12 | 105 |
| Stage 2 hypertension (SBP>=160 and DBP>=100 mmHg) | 13 | 8 | 0 | 24 |
Time from first intake of medication to first intake of an antihypertensive other than the study drug
| Days | Total |
|---|---|
| Time to First Additional Antihypertensive | 85.8 ± 38.4 |
The number of patients with DBP control (DBP\<90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment
| Participants | Pre-antihypertensive: Yes (DBP<90 mmHg) | Pre-antihypertensive: No (DBP>=90 mmHg) | Pre-antihypertensive: Total |
|---|---|---|---|
| Post-antihypertensive: Yes (DBP<90 mmHg) | 10 | 100 | 110 |
| Post-antihypertensive: No (DBP>=90 mmHg) | 2 | 106 | 108 |
| Post-antihypertensive: Total | 12 | 206 | 218 |
Difference in trough DBP from last visit before add-on therapy and last visit during 1235.7
| mmHg | Total |
|---|---|
| Additional Reduction in DBP by Use of Additional Antihypertensive Therapy | -5.73 ± 7.65 |
Difference in trough SBP from last visit before add-on therapy and last visit during 1235.7
| mmHg | Total |
|---|---|
| Additional Reduction in SBP by Use of Additional Antihypertensive Therapy | -7.53 ± 11.21 |
The number of patients with DBP control (DBP\<90 mmHg). Last trough DBP measurement before uptitration to Telmisartan 80mg compared to first trough DBP taken after uptitration
| Participants | Pre-titration: Yes (DBP<90 mmHg) | Pre-titration: No (DBP>=90 mmHg) | Pre-titration: Total |
|---|---|---|---|
| Post-titration: Yes (DBP<90 mmHg) | 17 | 190 | 207 |
| Post-titration: No (DBP>=90 mmHg) | 0 | 171 | 171 |
| Post-titration: Total | 17 | 361 | 378 |
Collected over From day of first dose until one day after last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Telmisartan 40mg and Amlodipine 5mg | — | 22/976 (2.3%) | 57/976 (5.8%) |
| Telmisartan 80mg and Amlodipine 5mg | — | 6/397 (1.5%) | 45/397 (11.3%) |
| Event | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/976 | 1/397 |
| Cardiac failureCardiac disorders | 0/976 | 1/397 |
| Mitral valve incompetenceCardiac disorders | 0/976 | 1/397 |
| Anal abscessInfections and infestations | 0/976 | 1/397 |
| Post procedural cellulitisInfections and infestations | 0/976 | 1/397 |
| Thyroid neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/976 | 1/397 |
| DizzinessNervous system disorders | 1/976 | 1/397 |
| HypotoniaNervous system disorders | 0/976 | 1/397 |
| Ovarian cystReproductive system and breast disorders | 0/976 | 1/397 |
| Uterine prolapseReproductive system and breast disorders | 0/976 | 1/397 |
| Event | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 25/976 | 24/397 |
| Oedema peripheralGeneral disorders | 32/976 | 21/397 |
| Age, Continuous(Years) | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive | Total |
|---|---|---|---|---|---|
| Mean | 54.8 ± 10.9 | 52.9 ± 10.6 | 54.4 ± 10.8 | 52.4 ± 9.6 | 53.9 ± 10.6 |
| Sex: Female, Male(Participants) | Telmisartan 40mg and Amlodipine 5mg | Telmisartan 80mg and Amlodipine 5mg | Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive | Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive | Total |
|---|---|---|---|---|---|
| Female | 240 | 72 | 8 | 45 | 365 |
| Male | 324 | 134 | 17 | 136 | 611 |
Showing the first 100 of 122 sites across 12 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2008 and a primary completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.